[A clinical study of fluconazole in the treatment of systemic mycosis associated with immunocompromised children].
Efficacies of fluconazole (FLCZ) were evaluated in 8 cases of systemic mycosis (1 case each of candidemia, candiduria, 4 cases of pulmonary candidiasis, and 2 cases of suspected fungemia) complicated in immunocompromised children. Enrolled in the study were 3 patients with acute leukemia, 1 with malignant lymphoma, 2 with congenital immunodeficiency syndrome, 2 with other disorders. The clinical efficacies were good in 6 out of 7 cases. No side effects were observed. FLCZ is a very good and safe agent for the treatment of systemic mycosis complicated with immunocompromised children.
Ishikawa
Y
Y
Department of Pediatrics, School of Medicine, Hokkaido University.
Shimizu
T
T
Sakiyama
Y
Y
Matsumoto
S
S
Hatae
Y
Y
Takeda
T
T
Ishikawa
A
A
Takase
A
A
Wagatsuma
Y
Y
D002177:Candidiasis / Q000188:drug therapy*; D002648:Child; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D016469:Fungemia / Q000188:drug therapy; D006801:Humans; D007108:Immune Tolerance; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007223:Infant; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male
D015725:Fluconazole